Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 882

1.

Acute infection and subsequent subclinical reactivation of herpes simplex virus-2 after vaginal inoculation of rhesus macaques.

Lo M, Zhu J, Hansen SG, Carroll T, Farr Zuend C, Nöel-Romas L, Ma ZM, Fritts L, Huang ML, Sun S, Huang Y, Koelle D, Picker LJ, Burgener A, Corey L, Miller CJ.

J Virol. 2018 Oct 17. pii: JVI.01574-18. doi: 10.1128/JVI.01574-18. [Epub ahead of print]

2.

Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons.

Ford ES, Magaret AS, Spak CW, Selke S, Kuntz S, Corey L, Wald A.

AIDS. 2018 Nov 13;32(17):2525-2531. doi: 10.1097/QAD.0000000000002002.

PMID:
30289810
3.

Environmental exposure to perchlorate: A review of toxicology and human health.

Pleus RC, Corey LM.

Toxicol Appl Pharmacol. 2018 Nov 1;358:102-109. doi: 10.1016/j.taap.2018.09.001. Epub 2018 Sep 2. Review.

PMID:
30184474
4.

A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection.

Schiffer JT, Swan DA, Roychoudhury P, Lund JM, Prlic M, Zhu J, Wald A, Corey L.

J Immunol. 2018 Sep 1;201(5):1522-1535. doi: 10.4049/jimmunol.1800471. Epub 2018 Jul 25.

PMID:
30045971
5.

Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals.

Agyemang E, Magaret AS, Selke S, Johnston C, Corey L, Wald A.

J Infect Dis. 2018 Oct 20;218(11):1691-1699. doi: 10.1093/infdis/jiy372.

PMID:
30020484
6.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

7.

Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants.

Boucoiran I, Mayer BT, Krantz EM, Marchant A, Pati S, Boppana S, Wald A, Corey L, Casper C, Schiffer JT, Gantt S.

Pediatr Infect Dis J. 2018 Jul;37(7):627-631. doi: 10.1097/INF.0000000000001877.

PMID:
29889809
8.

Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa.

Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, Cohen MS, Gilbert PB, Gray GE.

AIDS Res Hum Retroviruses. 2018 Aug;34(8):645-656. doi: 10.1089/AID.2018.0031. Epub 2018 Jun 19.

PMID:
29732896
9.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L.

Stat Commun Infect Dis. 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.

10.

Determination of Thresholds of Radioactive Iodine Uptake Response With Clinical Exposure to Perchlorate: A Pooled Analysis.

Bruce GM, Corey LM, Pearce EN, Braverman LE, Pleus RC.

J Occup Environ Med. 2018 Apr;60(4):e199-e206. doi: 10.1097/JOM.0000000000001239.

PMID:
29200191
11.

Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition.

Ramchandani M, Selke S, Magaret A, Barnum G, Huang MW, Corey L, Wald A.

Sex Transm Infect. 2017 Nov 25. pii: sextrans-2017-053244. doi: 10.1136/sextrans-2017-053244. [Epub ahead of print]

PMID:
29175899
12.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

13.

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network.

PLoS Med. 2017 Nov 14;14(11):e1002435. doi: 10.1371/journal.pmed.1002435. eCollection 2017 Nov.

14.

Adoptive Immunotherapy of Viral Infections: Should Infectious Disease Embrace Cellular Immunotherapy?

Boeckh M, Corey L.

J Infect Dis. 2017 Nov 15;216(8):926-928. doi: 10.1093/infdis/jix360. No abstract available.

PMID:
29029104
15.

Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children.

Matrajt L, Gantt S, Mayer BT, Krantz EM, Orem J, Wald A, Corey L, Schiffer JT, Casper C.

Sci Rep. 2017 Oct 12;7(1):13105. doi: 10.1038/s41598-017-12994-0.

16.

Broadly neutralizing antibodies to prevent HIV-1.

Cohen MS, Corey L.

Science. 2017 Oct 6;358(6359):46-47. doi: 10.1126/science.aap8131. No abstract available.

PMID:
28983040
17.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.

18.

Valganciclovir for the Suppression of Epstein-Barr Virus Replication.

Yager JE, Magaret AS, Kuntz SR, Selke S, Huang ML, Corey L, Casper C, Wald A.

J Infect Dis. 2017 Jul 15;216(2):198-202. doi: 10.1093/infdis/jix263.

19.

Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation.

Peng T, Chanthaphavong RS, Sun S, Trigilio JA, Phasouk K, Jin L, Layton ED, Li AZ, Correnti CE, De van der Schueren W, Vazquez J, O'Day DR, Glass IA, Knipe DM, Wald A, Corey L, Zhu J.

J Exp Med. 2017 Aug 7;214(8):2315-2329. doi: 10.1084/jem.20160581. Epub 2017 Jun 29.

20.

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.

Gilbert PB, Excler JL, Tomaras GD, Carpp LN, Haynes BF, Liao HX, Montefiori DC, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Kijak GH, Tovanabutra S, Francis DP, Lee C, Sinangil F, Berman PW, Premsri N, Kunasol P, O'Connell RJ, Michael NL, Robb ML, Morrow R, Corey L, Kim JH.

PLoS One. 2017 May 11;12(5):e0176428. doi: 10.1371/journal.pone.0176428. eCollection 2017.

Supplemental Content

Support Center